Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

A randomized, double-blind, placebo-controlled pilot study to assess the effects of protopanaxadiol saponin-enriched ginseng extract and pectinase-processed ginseng extract on the prevention of acute respiratory illness in healthy people

  • Hwang, Jeong-Hwan (Department of Internal Medicine, Jeonbuk National University Medical School) ;
  • Park, Soo-Hyun (Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital) ;
  • Choi, Eun-Kyung (Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital) ;
  • Jung, Su-Jin (Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital) ;
  • Pyo, Mi Kyung (International Ginseng and Herb Research Institute) ;
  • Chae, Soo-Wan (Clinical Trial Center for Functional Foods, Jeonbuk National University Hospital)
  • Received : 2018.05.08
  • Accepted : 2019.01.14
  • Published : 2020.09.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: GS-3K8 and GINST, both of which are modified ginseng extracts, have never been examined in terms of their effectiveness for the prevention of acute respiratory illness (ARI) in humans. We conducted a pilot study to assess the feasibility of performing a large-scale, randomized, controlled trial. Methods: This study was a randomized, double-blind, placebo-controlled, pilot study at a single center from October 2014 to March 2015. The 45 healthy applicants were randomly divided into the GS-3K8 (n = 15), GINST (n = 15), and placebo groups (n = 15). The study drug was administered as a capsule (500 mg/cap and 3000 mg/day). GS-3K8 contained 6.31 mg/g of Rg1, 15.05 mg/g of Re, 30.84 mg/g of Rb1, 15.02 mg/g of Rc, 12.44 mg/g of Rb2, 6.97 mg/g of Rd, 1.59 mg/g of Rg3, 3.25 mg/g of Rk1, and 4.84 mg/g of Rg5. GINST contained 7.54 mg/g of Rg1, 1.87 mg/g of Re, 5.42 mg/g of Rb1, 0.29 mg/g of Rc, 0.36 mg/g of Rb2, 0.70 mg/g of Rd, and 6.3 mg/g of compound K. The feasibility criteria were the rates of recruitment, drug compliance, and successful follow-up. The primary clinical outcome measure was the incidence of ARI. The secondary clinical outcome measures were the duration of symptoms. Results: The rate of recruitment was 11.3 participants per week. The overall rate of completed follow-up was 97.8%. The mean compliance rate was 91.64 ± 9.80%, 95.28 ± 5.75%, and 89.70 ± 8.99% in the GS-3K8, GINST, and placebo groups, respectively. The incidence of ARI was 64.3% (9/14; 95% confidence interval [CI], 31.4-91.1%), 26.7% (4/15; 95% CI, 4.3-49.0%), and 80.0% (12/15; 95% CI, 54.8-93.0%) in the GS-3K8, GINST, and placebo groups, respectively. The average days of symptoms were 3.89 ± 4.65, 9.25 ± 7.63, and 12.25 ± 12.69 in the GS-3K8, GINST, and placebo groups, respectively. Conclusion: The results support the feasibility of a full-scale trial. GS-3K8 and GINST appear to have a positive tendency toward preventing the development of ARI and reducing the symptom duration. A randomized controlled trial is needed to confirm these findings.

Keywords

References

  1. Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. CMAJ 2014;186:190-9. https://doi.org/10.1503/cmaj.121442
  2. Smith A, Thomas M, Whitney H. Effects of upper respiratory tract illnesses on mood and performance over the working day. Ergonomics 2000;43:752-63. https://doi.org/10.1080/001401300404724
  3. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003;163:487-94. https://doi.org/10.1001/archinte.163.4.487
  4. Health Insurance Review and Assessment Service (HIRA). The common cold in spring during the change of seasons, more attention in young people age group [Internet]. Seoul: HIRA; 2013. Mar [cited 2018 Feb 12]. Available from: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&brdScnBltNo=4&brdBltNo=8470.
  5. McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy and safety of CVT-E002, a proprietary extract of Panax quinquefolius in the prevention of respiratory infections in influenza-vaccinated community-dwelling adults: a multicenter, randomized, double-blind, and placebo-controlled trial. Influenza Res Treat 2011;2011:759051.
  6. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-74. https://doi.org/10.1016/S0140-6736(05)67339-4
  7. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One 2013;8:e60348. https://doi.org/10.1371/journal.pone.0060348
  8. Lee CS, Lee JH, Oh M, Choi KM, Jeong MR, Park JD, Kwon DY, Ha KC, Park EO, Lee N, et al. Preventive effect of Korean red ginseng for acute respiratory illness: a randomized and double-blind clinical trial. J Korean Med Sci 2012;27:1472-8. https://doi.org/10.3346/jkms.2012.27.12.1472
  9. McElhaney JE, Gravenstein S, Cole SK, Davidson E, O'neill D, Petitjean S, Rumble B, Shan JJ. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc 2004;52:13-9. https://doi.org/10.1111/j.1532-5415.2004.52004.x
  10. Shin BK, Kwon SW, Park JH. Chemical diversity of ginseng saponins from Panax ginseng. J Ginseng Res 2015;39:287-98. https://doi.org/10.1016/j.jgr.2014.12.005
  11. Lee MH, Lee BH, Lee S, Choi C. Reduction of hepatitis A virus on FRhK-4 cells treated with Korean red ginseng extract and ginsenosides. J Food Sci 2013;78:M1412-5. https://doi.org/10.1111/1750-3841.12205
  12. Lee MH, Seo DJ, Kang JH, Oh SH, Choi C. Expression of antiviral cytokines in Crandell-Reese feline kidney cells pretreated with Korean red ginseng extract or ginsenosides. Food Chem Toxicol 2014;70:19-25. https://doi.org/10.1016/j.fct.2014.04.034
  13. Liang YY, Wang B, Qian DM, Li L, Wang ZH, Hu M, Song XX. Inhibitory effects of Ginsenoside Rb1 on apoptosis caused by HSV-1 in human glioma cells. Virol Sin 2012;27:19-25. https://doi.org/10.1007/s12250-012-3220-6
  14. Bae EA, Kim NY, Han MJ, Choo MK, Kim DH. Transformation of ginsenosides to compound K(IH-901) by lactic acid bacteria of human intestine. J Microbiol Biotechnol 2003;13:9-14.
  15. Jin H, Seo JH, Uhm YK, Jung CY, Lee SK, Yim SV. Pharmacokinetic comparison of ginsenoside metabolite IH-901 from fermented and non-fermented ginseng in healthy Korean volunteers. J Ethnopharmacol 2012;139:664-7. https://doi.org/10.1016/j.jep.2011.11.052
  16. Seol SY, Kim BR, Hong SC, Yoo JH, Lee KH, Lee HJ, Park JD, Pyo MK. The effective preparation of protopanaxadiol saponin enriched fraction from ginseng using the ultrafiltration. Nat Prod Sci 2014;20:58-64.
  17. Park SH, Oh MR, Choi EK, Kim MG, Ha KC, Lee SK, Kim YG, Park BH, Kim DS, Chae SW. An 8-wk, randomized, double-blind, placebo-controlled clinical trial for the antidiabetic effects of hydrolyzed ginseng extract. J Ginseng Res 2014;38:239-43. https://doi.org/10.1016/j.jgr.2014.05.006
  18. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. https://doi.org/10.1111/j.1524-4733.2007.00213.x
  19. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, et al. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol 2012;10:195-201. https://doi.org/10.1016/j.suponc.2011.10.005
  20. Im K, Kim J, Min H. Ginseng, the natural effectual antiviral: protective effects of Korean Red Ginseng against viral infection. J Ginseng Res 2016;40:309-14. https://doi.org/10.1016/j.jgr.2015.09.002
  21. Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ 2005;173:1043-8. https://doi.org/10.1503/cmaj.1041470
  22. Seida JK, Durec T, Kuhle S. North American (Panax quinquefolius) and Asian ginseng (Panax ginseng) preparations for prevention of the common cold in healthy adults: a systematic review. Evid Based Complement Alternat Med:eCAM 2011;2011:282151.
  23. Wang Y, Jung YJ, Kim KH, Kwon Y, Kim YJ, Zhang Z, Kang HS, Wang BZ, Quan FS, Kang SM. Antiviral activity of fermented ginseng extracts against a broad range of influenza viruses. Viruses 2018;10.
  24. Pyo MK, Seol SY, Yoo JH, Lee KH, Hong SC, Park JD, International Ginseng & Herb Research Institute. Composition of anti-influenza H1N1 virus using ultrafiltration and preparation method thereof. Korean patent KR 101485982B1. 2015 Jan 19. Korean.

Cited by

  1. Ginseng integrative supplementation for seasonal acute upper respiratory infections: A systematic review and meta-analysis vol.52, 2020, https://doi.org/10.1016/j.ctim.2020.102457
  2. Pharmacological Efficacy of Ginseng against Respiratory Tract Infections vol.26, pp.13, 2020, https://doi.org/10.3390/molecules26134095
  3. Effect of Ginseng Extracts on the Improvement of Osteopathic and Arthritis Symptoms in Women with Osteopenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial vol.13, pp.10, 2020, https://doi.org/10.3390/nu13103352
  4. Efficacy of the commercial plant products acting against influenza-a review vol.7, pp.1, 2020, https://doi.org/10.1186/s43094-021-00385-2